PI3 - peptidase inhibitor 3 Gene

中文名称：肽酶抑制因子 3

种属: Homo sapiens

同用名: ESI; WAP3; SKALP; WFDC14; cementoin

基因 ID: 5266 | 基因类型: protein coding

关于 PI3

Cytogenetic location: 20q13.12 Genomic coordinates (GRCh38): 20:45,174,902-45,176,544 (from NCBI)

This gene has 1 transcript (splice variant), 80 orthologues and 9 paralogues. Biased expression in esophagus (RPKM 578.7), colon (RPKM 50.5) and 1 other tissue.

功能概要

该基因编码一种弹性蛋白酶特异性抑制剂，可作为抗革兰氏阳性和革兰氏阴性细菌以及真菌病原体的抗菌肽。该蛋白质包含一个 WAP 型四二硫核心 (WFDC) 结构域，因此是 WFDC 结构域家族的成员。大多数 WFDC 基因成员位于染色体 20q12-q13 的两个簇中：着丝粒和端粒。该基因属于着丝粒簇。该基因的表达受细菌脂多糖和细胞因子的上调。[RefSeq 提供，2014 年 10 月]

This gene encodes an elastase-specific inhibitor that functions as an antimicrobial peptide against Gram-positive and Gram-negative bacteria, and Fungal pathogens. The protein contains a WAP-type four-disulfide core (WFDC) domain, and is thus a member of the WFDC domain family. Most WFDC gene members are localized to chromosome 20q12-q13 in two clusters: centromeric and telomeric. This gene belongs to the centromeric cluster. Expression of this gene is upgulated by Bacterial lipopolysaccharides and cytokines. [provided by RefSeq, Oct 2014]

PI3 基因产物(1)

mRNA	Protein	Name
NM_002638.4	NP_002629.1	elafin preproprotein

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables structural constituent of skin epidermis	IDA IDA: 通过直接分析推断	7543090	GOA

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in peptide cross-linking	IDA IDA: 通过直接分析推断	7543090	GOA

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cornified envelope	IDA IDA: 通过直接分析推断	7543090	GOA

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

PI3 蛋白结构

Cementoin

WAP

0
100
117 a.a.

蛋白主名

其他名称

elafin

PI-3

重组 PI3 蛋白

目录号	产品名	蛋白编号	纯度
HY-P70316	Elafin/Trappin-2 Protein, Human (HEK293, His)	P19957 (A23-Q117)	≥95%

关联疾病

疾病名称

别名

Pustular Psoriasis

Farmer'S Lung

Farmer Lung	Farmers Lung
Farmer'S Lung Disease	Farmers' Lung
Farmers' Lung Disease	Mouldy Hay Disease
Moldy Hay Disorder	Fibrosis Of Lung With Farmers' Lung
Harvesters' Hypersensitivity Pneumonitis	Moldy Hay Pneumoconiosis
Haymakers' Hypersensitivity Pneumonitis	Threshers' Lung
Harvester Lung	Haymaker Lung

Extrinsic Allergic Alveolitis

Hypersensitivity Pneumonitis	Alveolitis, Extrinsic Allergic
Alveolitis	Allergic Interstitial Pneumonitis
Allergic Pneumonitis	Extrinsic Allergic Pneumonia Hypersensitivity Pneumonitis
Hp	Pneumonitis Hypersensitivity
Allergic Alveolitis	Extrinsic Allergic Alveolitis Nos
Airway Obstruction With Allergic Alveolitis	Unspecified Allergic Alveolitis And Pneumonitis
Extrinsic Allergic Bronchiolo-Alveolitis	Hypersensitivity Pneumonia
Hypersensitivity Pneumonitis Nos	Obstructive Lung Disease With Allergic Alveolitis
Obstructive Lung Disorder With Hypersensitivity Pneumonitis	Obstructive Lung Disorder With Allergic Alveolitis
Obstructive Lung Disease With Hypersensitivity Pneumonitis

Erysipelas

Adult Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome	Ards
Non-Cardiogenic Pulmonary Edema	Acute Lung Injury
Respiratory Distress Syndrome, Adult	Shock Lung
Acute Respiratory Distress	Respiratory Distress Syndrome
Adult Rds	Ali
Increased-Permeability Pulmonary Edema	Stiff Lung
Respiratory Distress Syndrome Adult

Impetigo

Netherton Syndrome

NETH	Ns
Netherton Disease	Comel-Netherton Syndrome
Erythroderma, Ichthyosiform, With Hypotrichosis And Hyper-Ige	Bamboo Hair Syndrome
Ichthyosis Linearis Circumflexa	Ichthyosiform Erythroderma With Hypotrichosis And Hyper-Ige
Ilc	Nts
N Syndrome

Allergic Contact Dermatitis

Dermatitis, Allergic Contact	Contact Dermatitis, Allergic
Dermatitis Allergic Contact	Allergic Contact Eczema
Acd - [Allergic Contact Dermatitis]	Allergic Contact Dermatitis, Unspecified Cause
Allergic Dermatitis	Allergic Eczema
Allergy Dermatitis	Allergy Eczema
Allergic Contact Eczema Due To Clothing Or Footwear	Perfume Allergic Contact Dermatitis
Allergic Contact Dermatitis Due To Cosmetics	Allergic Contact Eczema Due To Cosmetics Or Fragrances
Allergic Contact Eczema Due To Dental Materials	Allergic Contact Eczema Due To Food Flavours Or Additives
Allergic Contact Eczema Due To Hairdressing Products	Allergic Contact Eczema Due To Metals Or Metal Salts
Allergic Contact Eczema Due To Proteins	Allergic Contact Eczema Due To Plastics Or Resin Systems
Allergic Contact Eczema Due To Preservatives Or Biocides	Allergic Contact Eczema Due To Rubber Chemicals
Rubber Dermatitis	Allergic Contact Eczema Due To Systemic Medicaments
Allergic Contact Eczema Due To Topical Medicaments	Allergic Contact Dermatitis Due To Drugs In Contact With Skin

Lung Disease

Lung Diseases	Disorder Of Lung
Abnormality Of The Lung

Psoriasis

Corneal Abscess

Double Pterygium

Pasteurellosis

Pasteurella Infection	Pasteurella Infections
Pasteurella Infectious Disease	Shipping Fever
Transport Fever

Skin Disease

Skin Diseases	Genodermatosis
Abnormality Of The Skin	Skin Diseases, Genetic
Skin And Subcutaneous Tissue Disease	Dermatologic Disorders

Cystic Fibrosis

Mucoviscidosis	CF
Pseudomonas Aeruginosa, Susceptibility To Chronic Infection By, In Cystic Fibrosis	Pseudomonas Aeruginosa Chronic Infection By, In Cystic Fibrosis
Cystic Fibrosis Lung Disease, Modifier Of	Cystic Fibrosis Of Pancreas
Fibrocystic Disease Of Pancreas	Cf - [Cystic Fibrosis]
Cystic Fibrosis Nos	Fibrocystic Disease
Fibrocystic Disease Of The Pancreas	Mucoviscidosis Of Pancreas
Nonproliferative Fibrocystic Disease	Pancreatic Cystic Fibrosis

Familiar Ovarian Carcinoma

Bacterial Infectious Disease

Bacterial Infections	Bacterial Infection Nos
Disease Caused By Bacteria	Bacterial Disease Or Disorder

Type 1 Diabetes Mellitus 8

Diabetes Mellitus, Insulin-Dependent, 8	Iddm8
Insulin-Dependent Diabetes Mellitus 8	T1D8
Insulin-Dependent Diabetes Mellitus-8

Preterm Premature Rupture Of The Membranes

Preterm Premature Rupture Of Membranes	PPROM
Preterm Premature Rupture Of The Membranes, Susceptibility To	Pprom - [Preterm Premature Rupture Of Membranes]
Preterm Rupture Of Membranes

Pulmonary Disease, Chronic Obstructive

Chronic Obstructive Pulmonary Disease	COPD
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset	Chronic Obstructive Lung Disease
Chronic Obstructive Airway Disease	Pulmonary Disease, Chronic Obstructive, Susceptibility To
Cold	Severe Early-Onset Chronic Obstructive Pulmonary Disease
Pulmonary Disease Chronic Obstructive	Pulmonary Disease, Obstructive, Chronic, Susceptibility To
Chronic Obstructive Pulmonary Disease Of Horses	Common Cold
Upper Respiratory Infections	Copd - [Chronic Obstructive Pulmonary Disease]
Coad - [Chronic Obstructive Airways Disease]	Cold - [Chronic Obstructive Lung Disease]
Chronic Airway Disease Nos	Chronic Airways Limitation, Unspecified
Chronic Obstructed Airway, Unspecified	Chronic Obstructive Airway Disease, Unspecified
Chronic Obstructive Airway, Unspecified	Obstructive Lung Disease Nos
Chronic Obstructive Lung Disease Nos	Chronic Obstructive Lung Nos
Obstructive Pulmonary Disease Nos	Exacerbation Copd Nos
Acute Exacerbation Copd

Parotid Gland Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma Of Parotid Gland

Joubert Syndrome 7

JBTS7	Cerebello-Oculo-Renal Syndrome 3
Cors3	Joubert Syndrome, Type 7

Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Bowel Disease, Inflammatory

Basal Cell Carcinoma

Basal Cell Cancer	Basal Cell Neoplasm
Basal Cell Carcinoma Of Skin	Malignant Basal Cell Tumor
Basal Cell Tumor	Epithelioma Basal Cell
Malignant Basal Cell Neoplasm	Rodent Ulcer
Carcinoma Basal Cell	Neoplasms, Basal Cell
Basal Cell Carcinomas	Experimental Organism Basal Cell Carcinoma
Nodulo-Ulcerative Basal Cell Carcinoma	Basalioma
Basal Cell Epithelioma Of Skin	Bcc - [Basal Cell Carcinoma] Of Skin
Rodent Ulcer Of Skin	Rodent Ulcer Of Unspecified Site
Basal Cell Epithelioma Of Unspecified Site

疾病名称	别名
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

相关产品

Approval

生物活性分子 (34)

目录号	产品名	作用方式	纯度	是否罕见病
HY-18085	Quercetin		99.80%	是
HY-15244	Alpelisib	Inhibitor	99.95%	是
HY-13026	Idelalisib		99.78%	是
HY-101562	Inavolisib		99.96%	否
HY-15346	Copanlisib		99.50%	否
HY-17508	Clarithromycin	Inhibitor	99.90%	是
HY-15346A	Copanlisib dihydrochloride		99.55%	是
HY-N0717	L-Valine		99.89%	否
HY-B0965	Thioridazine hydrochloride		99.96%	否
HY-B0648	Medroxyprogesterone	Agonist	99.30%	否
HY-13685	Miltefosine	Inhibitor	99.92%	是
HY-N0146	Quercetin dihydrate		≥97.0%	是
HY-12279	Umbralisib	Inhibitor	98.94%	是
HY-14151	Prucalopride		99.81%	是
HY-14153A	Tegaserod maleate		99.90%	否
HY-B0766	Bicyclol		99.91%	否
HY-14153	Tegaserod		99.89%	否
HY-12694	Prucalopride succinate		99.95%	是
HY-15856B	Flupentixol dihydrochloride		99.73%	是
HY-B0319	Tioconazole	Inhibitor	99.90%	否
HY-B0093A	Benazepril hydrochloride	Inhibitor	99.96%	是
HY-B1234	Octinoxate		99.89%	否
HY-B0093	Benazepril		99.32%	是
HY-12279C	Umbralisib hydrochloride	Inhibitor	99.04%	是
HY-N0717R	L-Valine (Standard)		/	否
HY-12279A	Umbralisib tosylate	Inhibitor	/	否
HY-12279B	Umbralisib sulfate	Inhibitor	/	否
HY-15244A	Alpelisib hydrochloride	Inhibitor	/	否
HY-B0965A	Thioridazine		/	否
HY-15856A	Flupentixol		/	否
HY-15856BR	Flupentixol dihydrochloride (Standard)		/	否
HY-17508R	Clarithromycin (Standard)	Inhibitor	/	否
HY-B0093AR	Benazepril (hydrochloride) (Standard)	Inhibitor	/	否
HY-B0965R	Thioridazine (hydrochloride) (Standard)		/	否

Clinical Phase

生物活性分子 (75)

目录号	产品名	作用方式	纯度	Phase
HY-N0728	α-Linolenic acid	Inhibitor	99.92%	Phase 4
HY-18085G	Quercetin (GMP)		/	Phase 4
HY-W753806	Doxazosin hydrochloride	Inhibitor	/	Phase 4
HY-70063	Buparlisib		99.90%	Phase 3
HY-50673	Dactolisib		99.94%	Phase 3
HY-13898	Taselisib	Inhibitor	99.75%	Phase 3
HY-10681	Gedatolisib	Inhibitor	99.68%	Phase 3
HY-12037A	Rigosertib		99.01%	Phase 3
HY-N0104	Curcumol	Inducer	99.50%	Phase 3
HY-D0803	Thymoquinone		99.59%	Phase 3
HY-17635	Leniolisib	Inhibitor	99.28%	Phase 3
HY-12037	Rigosertib sodium		99.57%	Phase 3
HY-109068	Parsaclisib	Inhibitor	99.31%	Phase 3
HY-15174	Dactolisib Tosylate		99.87%	Phase 3
HY-15180	Buparlisib Hydrochloride		99.88%	Phase 3
HY-109198	Zandelisib	Inhibitor	99.90%	Phase 3
HY-17635A	Leniolisib phosphate	Inhibitor	99.10%	Phase 3
HY-109068A	Parsaclisib hydrochloride	Inhibitor	98.74%	Phase 3
HY-106263B	Tyroserleutide hydrochloride		99.47%	Phase 3
HY-50094	Pictilisib		99.80%	Phase 2
HY-100716	Eganelisib	Inhibitor	99.68%	Phase 2
HY-139609	Camonsertib	Inhibitor	99.75%	Phase 2
HY-19719	Miransertib	Inhibitor	99.32%	Phase 2
HY-13522	Fimepinostat		99.95%	Phase 2
HY-15245	GSK2636771	Inhibitor	99.83%	Phase 2
HY-15177	PF-04691502		99.91%	Phase 2
HY-12513	Samotolisib		99.27%	Phase 2
HY-12330	AZD8186	Inhibitor	99.97%	Phase 2
HY-10111	TG100-115	Inhibitor	99.41%	Phase 2
HY-13246	Apitolisib		99.29%	Phase 2
HY-102031	Linperlisib	Inhibitor	99.51%	Phase 2
HY-15900	Voxtalisib	Inhibitor	99.02%	Phase 2
HY-12868	Bimiralisib	Inhibitor	99.80%	Phase 2
HY-13334A	BGT226		99.51%	Phase 2
HY-16526	Pilaralisib	Inhibitor	98.81%	Phase 2
HY-13334	BGT226 maleate		99.87%	Phase 2
HY-N9481	Lipoteichoic acid		/	Phase 2
HY-19535A	Nemiralisib	Inhibitor	99.80%	Phase 2
HY-17645	Tenalisib	Inhibitor	98.83%	Phase 2
HY-10202	Tandutinib		99.48%	Phase 2
HY-N6775	Sonolisib	Inhibitor	99.00%	Phase 2
HY-12948	AMG319	Inhibitor	99.08%	Phase 2
HY-20180	Pictilisib dimethanesulfonate		99.72%	Phase 2
HY-16754	Seletalisib	Inhibitor	99.79%	Phase 2
HY-19719A	Miransertib hydrochloride	Inhibitor	99.74%	Phase 2
HY-132601	Cobomarsen	Inhibitor	/	Phase 2
HY-10202A	Tandutinib hydrochloride		99.78%	Phase 2
HY-10220	SF1126	Inducer	/	Phase 2
HY-135827A	Roginolisib hemifumarate	Inhibitor	99.80%	Phase 2
HY-P0118	Disitertide		/	Phase 2
HY-123823	Nitroaspirin		/	Phase 2
HY-P0118A	Disitertide TFA		/	Phase 2
HY-19535	Nemiralisib hydrochloride	Inhibitor	/	Phase 2
HY-109029	Dezapelisib	Inhibitor	/	Phase 2
HY-10108	LY294002		99.95%	Phase 1
HY-101625	Recilisib	Activator	99.94%	Phase 1
HY-10297	Omipalisib		99.93%	Phase 1
HY-153306	RLY-2608	Inhibitor	99.20%	Phase 1
HY-50847	ZSTK474		99.88%	Phase 1
HY-N2037A	Higenamine hydrochloride		99.68%	Phase 1
HY-19896	COTI-2		99.66%	Phase 1
HY-12036	GSK1059615		≥99.0%	Phase 1
HY-16585	VS-5584	Inhibitor	99.14%	Phase 1
HY-15837	SAR-260301	Inhibitor	99.95%	Phase 1
HY-100886	BAY1082439		98.02%	Phase 1
HY-N2037	Higenamine		98.91%	Phase 1
HY-12644	Acalisib	Inhibitor	99.98%	Phase 1
HY-12869	AZD-8835	Inhibitor	98.62%	Phase 1
HY-15466	Izorlisib	Inhibitor	99.01%	Phase 1
HY-121246	Fluorofenidone		99.65%	Phase 1
HY-162472	XRD-0394	Inhibitor	98.54%	Phase 1
HY-11080A	PKI-179 hydrochloride	Inhibitor	99.66%	Phase 1
HY-124036	DS-7423	Inhibitor	99.75%	Phase 1
HY-100694	GS-9901	Inhibitor	99.97%	Phase 1
HY-101625A	Recilisib sodium	Activator	/	Phase 1

Pre-clinical Phase

生物活性分子 (520)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-19312	3-Methyladenine	Inhibitor	99.91%	否
HY-P0175	740 Y-P		99.96%	否
HY-10197	Wortmannin	Inhibitor	99.86%	否
HY-12016	KU-55933	Inhibitor	99.92%	否
HY-11006	KU-57788		99.95%	否
HY-12481	SAR405	Inhibitor	99.74%	否
HY-13002	Torin 2		99.65%	否
HY-N0776	Isorhamnetin	Inhibitor	99.94%	否
HY-10115	PI-103		99.82%	否
HY-156681	STX-478	Inhibitor	99.63%	否
HY-154848	UCL-TRO-1938	Activator	99.98%	否
HY-110171	iMDK	Inhibitor	99.35%	否
HY-N0451	Acacetin	Inducer	99.83%	否
HY-124719	hSMG-1 inhibitor 11j	Inhibitor	99.82%	否
HY-151527	PI3K/Akt/CREB activator 1		98.64%	否
HY-12795	Vps34-IN-1		99.79%	否
HY-131615	TPC2-A1-P	Agonist	99.76%	否
HY-D0254	Gallein		≥98.0%	否
HY-N0270	Ononin		99.96%	否
HY-15719	NU 7026		99.86%	否
HY-144806	PI3K/AKT-IN-1		99.64%	否
HY-13425	Deguelin		99.20%	否
HY-N0787	Cryptochlorogenic acid		99.87%	否
HY-N2515	Ginsenoside Rk1		99.90%	否
HY-15477	YS-49		99.92%	否
HY-N0361	Dihydrocapsaicin		99.93%	否
HY-N0284	Esculetin	Inhibitor	99.78%	否
HY-N0031	Plantamajoside		99.52%	否
HY-12030	PIK-90	Inhibitor	99.70%	否
HY-N1435	Oroxin B		99.71%	否
HY-N0076	Bilobalide	Inhibitor	≥98.0%	否
HY-N0457	Chicoric acid	Inducer	99.95%	否
HY-N0330	Momordin Ic		99.71%	否
HY-19962	Paxalisib	Inhibitor	99.63%	是
HY-124760	hSMG-1 inhibitor 11e	Inhibitor	99.81%	否
HY-10114	TGX-221	Inhibitor	99.74%	否
HY-N1381	Periplocin	Inducer	99.92%	否
HY-P0118B	Disitertide diammonium		99.53%	否
HY-116035	Nimbolide		99.79%	否
HY-P1925A	GO-203 TFA		99.28%	否
HY-13532	AS-252424	Inhibitor	99.71%	否
HY-12046	PIK-93	Inhibitor	99.81%	否
HY-103450	G36	Antagonist	99.66%	否
HY-N0022	Isoacteoside		99.73%	否
HY-18676	OSU-T315		99.88%	否
HY-12794	Vps34-PIK-III	Inhibitor	99.63%	否
HY-16596	CNX-1351	Inhibitor	99.88%	否
HY-N0448	10-Gingerol		99.66%	否
HY-150795	SY-LB-35		≥98.0%	否
HY-10110	IC-87114	Inhibitor	99.83%	否
HY-15290	AIM-100	Inhibitor	99.95%	否
HY-N0103	Sophocarpine		98.63%	否
HY-N0847	Micheliolide	Inhibitor	99.84%	否
HY-N1346	Robinin		98.77%	否
HY-12068	PI3K-IN-1	Inhibitor	99.93%	否
HY-143404	PI3K-IN-30	Inhibitor	98.21%	否
HY-10044	WYE-132		99.90%	否
HY-122862	RAS inhibitor Abd-7	Inhibitor	99.16%	否
HY-110171A	iMDK quarterhydrate	Inhibitor	99.37%	否
HY-N6739	Beauvericin		99.97%	否
HY-13431	KU-0060648	Inhibitor	99.62%	否
HY-P4322	H-Ile-Lys-Val-Ala-Val-OH	Activator	99.42%	否
HY-W010201	Citronellol		98.60%	否
HY-10109	AS-605240		98.51%	否
HY-10683	PKI-402	Inhibitor	98.43%	否
HY-146751	PI3K/Akt/mTOR-IN-2		99.93%	否
HY-N2187	Deoxyshikonin		99.96%	否
HY-11002	CP-466722	Inhibitor	99.91%	否
HY-117163	FzM1.8	Agonist	98.37%	否
HY-N2045	Musk ketone		99.41%	否
HY-N2447	Amarogentin		99.93%	否
HY-14971	(E)-Akt inhibitor-IV	Inhibitor	99.89%	否
HY-160093	SQLE-IN-1		98.82%	否
HY-12763	GNE-317	Inhibitor	99.14%	否
HY-139534	ARI-1		99.76%	否
HY-141807	MS21		99.88%	否
HY-156406	PITCOIN4	Inhibitor	99.97%	否
HY-N0314	Pectolinarin		99.89%	否
HY-112443	AZD3458	Inhibitor	99.71%	否
HY-10115A	PI-103 Hydrochloride		98.55%	否
HY-111570	PI3Kγ inhibitor AZ2	Inhibitor	99.25%	否
HY-N7204	4-Hydroxyderricin		99.97%	否
HY-107365	PQR530	Inhibitor	99.98%	否
HY-P2196A	ELA-32(human) TFA	Agonist	99.27%	否
HY-101146	SF2523	Inhibitor	98.25%	否
HY-135827	Roginolisib	Inhibitor	99.89%	否
HY-124652	TBK1/IKKε-IN-4	Inhibitor	99.42%	否
HY-N2491	Deoxyelephantopin	Inhibitor	99.03%	否
HY-N6002	3'-Hydroxypterostilbene	Inducer	99.89%	否
HY-101667	LTURM34	Inhibitor	99.35%	否
HY-162713	MTX-531		99.87%	否
HY-15672	FM19G11	Inhibitor	98.39%	否
HY-131015	HaXS8		98.69%	否
HY-13440	AMG 511	Inhibitor	99.38%	否
HY-17587	4-Methylbenzylidene camphor		99.87%	否
HY-15643A	LY 303511 hydrochloride		98.87%	否
HY-17044A	Duvelisib (R enantiomer)	Inhibitor	/	否
HY-100385	Brevianamide F	Inhibitor	99.03%	否
HY-121222	alpha-Bisabolol		≥80.0%	否
HY-N0103A	Sophocarpine monohydrate		99.91%	否
HY-N0479	Licarin B	Activator	99.93%	否
HY-N2112	Glaucocalyxin A		99.39%	否
HY-12235	PI-3065	Inhibitor	98.97%	否
HY-10108A	LY294002 hydrochloride		99.47%	否
HY-101272	GDC-0326	Inhibitor	99.92%	否
HY-19798	PI4KIIIbeta-IN-9	Inhibitor	99.01%	否
HY-112440	HZX-02-059	Activator	99.40%	否
HY-131972	PF-06843195	Inhibitor	98.01%	否
HY-143403	PI3K-IN-31	Inhibitor	99.55%	否
HY-150618	PI3Kα-IN-9		99.17%	否
HY-18085A	Quercetin hydrate		98.45%	否
HY-N6263	EGCG Octaacetate	Inhibitor	98.42%	否
HY-112897	IITZ-01		98.18%	否
HY-12034	WYE-354		98.04%	否
HY-136268	AQX-435	Activator	99.19%	否
HY-106012	PI4K-IN-1	Inhibitor	98.61%	否
HY-120213	YH-306		98.34%	否
HY-13531	AS-604850	Inhibitor	99.95%	否
HY-15294	CZC24832	Inhibitor	99.07%	否
HY-N6843	Arnicolide D		99.20%	否
HY-10811	GNE-493	Inhibitor	99.81%	否
HY-100470	NSC781406	Inhibitor	99.97%	否
HY-107364	MTX-211	Inhibitor	99.81%	否
HY-15868	HS-173		99.04%	否
HY-115870	AZD8154	Inhibitor	99.88%	否
HY-100398	PF-04979064	Inhibitor	99.54%	否
HY-100603	GSK-F1	Inhibitor	95.00%	否
HY-115620	AQX-016A		98.00%	否
HY-N1967	Dihydrocurcumin	Inhibitor	99.77%	否
HY-N6950	Hederacolchiside A1		99.69%	否
HY-111508	PI3K/mTOR Inhibitor-2	Inhibitor	99.10%	否
HY-110109	ETP-45658	Inhibitor	98.97%	否
HY-153894	SRX3177	Inhibitor	99.59%	否
HY-N0392	Polygalasaponin F	Inhibitor	99.85%	否
HY-N3354	Lupiwighteone	Inducer	99.52%	否
HY-N5112B	β,β-Dimethylacrylshikonin		99.30%	否
HY-N6017	Bakkenolide A	Inhibitor	99.99%	否
HY-11042	GNE-477	Inhibitor	98.75%	否
HY-118717	mTOR inhibitor WYE-28	Inhibitor	99.75%	否
HY-110193	SPP-86	Inhibitor	99.62%	否
HY-11080	PKI-179	Inhibitor	≥98.0%	否
HY-N5072	Desmethylglycitein	Inhibitor	98.98%	否
HY-N6064	Polygalacin D		99.95%	否
HY-13530	CAY10505		99.75%	否
HY-136198	SRX3207	Inhibitor	98.50%	否
HY-108606	PI-828	Inhibitor	99.62%	否
HY-123952	RTC-5	Inhibitor	99.89%	否
HY-128333	PI3K/mTOR Inhibitor-4	Inhibitor	97.00%	否
HY-13333	NVP-BAG956	Inhibitor	99.21%	否
HY-15271	WYE-687	Inhibitor	98.05%	否
HY-156371	MIPS-21335	Inhibitor	99.61%	否
HY-19312S	3-Methyladenine-d3		99.44%	否
HY-19763	BEBT-908	Inhibitor	99.60%	否
HY-N6896	Isoviolanthin	Inhibitor	99.66%	否
HY-103224	PIT-1	Inhibitor	98.56%	否
HY-112613	UCB9608	Inhibitor	99.59%	否
HY-12652	AZD3147	Inhibitor	99.93%	否
HY-13514	TG 100713	Inhibitor	99.49%	否
HY-147768	PI3K/AKT-IN-2		98.10%	否
HY-156681A	(S)-STX-478	Control	99.18%	否
HY-163677	ARM165	Inhibitor	99.75%	否
HY-N4042	Hirsutenone	Inhibitor	99.74%	否
HY-111510	IPI-3063	Inhibitor	99.22%	否
HY-112608	CHMFL-PI3KD-317	Inhibitor	98.04%	否
HY-132231	FD223		98.05%	否
HY-147419	Vulolisib	Inhibitor	99.60%	否
HY-108016	Peruvoside		99.32%	否
HY-130413	Protectin D1		99.10%	否
HY-137340	WH-10417-099		98.14%	否
HY-143275	HL-8	Inhibitor	99.17%	否
HY-19341	Compound 401	Inhibitor	99.97%	否
HY-N3035	Tetrahydroepiberberine	Inhibitor	99.20%	否
HY-N3127	Orobol	Inhibitor	99.28%	否
HY-18650	KU 59403	Inhibitor	99.23%	否
HY-151622	PI3K/mTOR Inhibitor-11	Inhibitor	98.74%	否
HY-101921	PI3Kδ-IN-1	Inhibitor	99.60%	否
HY-131345A	(S)-PI3Kα-IN-4	Inhibitor	99.77%	否
HY-112172	Tenalisib R Enantiomer		99.63%	否
HY-118521	AS-041164	Inhibitor	99.02%	否
HY-132601A	Cobomarsen sodium		92.58%	否
HY-136512	Streptazolin		98.65%	否
HY-144993	PI3Kδ/γ-IN-1	Inhibitor	99.85%	否
HY-149091	KDM5B-IN-4	Inhibitor	99.68%	否
HY-15280	GSK2292767	Inhibitor	98.89%	否
HY-153120A	PI3K/mTOR Inhibitor-13 sodium	Inhibitor	98.13%	否
HY-162382	KTC1101	Inhibitor	98.09%	否
HY-17508S1	Clarithromycin-d3	Inhibitor	99.90%	否
HY-17635S	Leniolisib-d5	Inhibitor	98.78%	否
HY-N2590	Lupenone	Inhibitor	99.74%	否
HY-N3260	Methyllucidone		≥98.0%	否
HY-N7363	Isolongifolene	Inhibitor	98.4%	否
HY-12340	ETP-46321	Inhibitor	99.34%	否
HY-126049	(S)-Oxiracetam	Inhibitor	98.78%	否
HY-15477A	YS-49 monohydrate		99.71%	否
HY-101776A	Desmethyl-VS-5584 hydrochloride	Inhibitor	98.63%	否
HY-11105	Pilaralisib analogue		99.74%	否
HY-111383	LX2343		99.80%	否
HY-101517	PI3K-IN-2	Inhibitor	/	否
HY-131345	PI3Kα-IN-4	Inhibitor	99.76%	否
HY-133124	PARP/PI3K-IN-1		99.43%	否
HY-18085S1	Quercetin-d3		/	否
HY-B0965AS	Thioridazine-d3 hydrochloride		99.19%	否
HY-103030	PI3K-IN-32	Inhibitor	99.7%	否
HY-10620	PI3K-IN-22	Inhibitor	99.50%	否
HY-108418A	(R)-PI3Kδ-IN-15	Control	99.52%	否
HY-109633	PI3K-IN-18	Inhibitor	≥99.0%	否
HY-109633A	PI3K-IN-18 dihydrochloride	Inhibitor	99.70%	否
HY-120438	TASP0415914	Inhibitor	99.02%	否
HY-125542	DCZ3301		99.73%	否
HY-12895	SKI V		98.95%	否
HY-130307	Rubrofusarin	Inhibitor	98.19%	否
HY-131502	Taspine	Inhibitor	/	否
HY-133907	NVS-PI3-4	Inhibitor	99.40%	否
HY-13504	PIK-293	Inhibitor	99.41%	否
HY-13864	PF-4989216		99.38%	否
HY-145526	Hydroxy celecoxib	Activator	/	否
HY-147284	PI3K-IN-37	Inhibitor	≥99.0%	否
HY-14971A	AKT inhibitor IV	Inhibitor	99.0%	否
HY-150019	PI3K-IN-36	Inhibitor	98.76%	否
HY-15271A	WYE-687 dihydrochloride	Inhibitor	≥98.0%	否
HY-155066	FD274	Inhibitor	99.45%	否
HY-155232	PI3Kδ-IN-16		99.02%	否
HY-157169	IBL-302	Inhibitor	98.21%	否
HY-16122B	CAL-130 Hydrochloride	Inhibitor	98.74%	否
HY-161366	OMS14	Inhibitor	99.09%	否
HY-18085AS	Quercetin-d3 hydrate		/	否
HY-N0728S	α-Linolenic acid-d5	Inhibitor	/	否
HY-N0728S3	α-Linolenic acid-13C18	Inhibitor	97.40%	否
HY-N2051	Zeylenone	Activator	≥98.0%	否
HY-N2602	Sanggenol L	Inhibitor	98.90%	否
HY-N5136	25(R,S)-Ruscogenin	Inhibitor	99.83%	否
HY-W005308	N-BOC-DL-serine methyl ester		≥97.0%	否
HY-W130965	1-Formyl-beta-carboline	Inhibitor	99.70%	否
HY-108418	PI3Kδ-IN-15	Inhibitor	99.52%	否
HY-121435	K-8012		98.24%	否
HY-12338	ON 146040	Inhibitor	95.05%	否
HY-16355	NVP-QAV-572	Inhibitor	98.05%	否
HY-U00326	PI3Kα/mTOR-IN-1	Inhibitor	99.30%	否
HY-10812	GNE-490	Inhibitor	96.29%	否
HY-101798	MDVN1003	Inhibitor	/	否
HY-142646	PI3Kδ-IN-9	Inhibitor	/	否
HY-144876	RIDR-PI-103	Inducer	98.02%	否
HY-128582	PI3K/HDAC-IN-1	Inhibitor	/	否
HY-132880	GSK251	Inhibitor	99.88%	否
HY-151137	HSP90/mTOR-IN-1		/	否
HY-101114	LAS191954	Inhibitor	/	否
HY-101115	PI3K-IN-6	Inhibitor	/	否
HY-131910	IHMT-PI3Kδ-372	Inhibitor	/	否
HY-132299	PI3Kγ inhibitor 4	Inhibitor	/	否
HY-132807	Amdizalisib	Inhibitor	/	否
HY-133029	PI3K-IN-9	Inhibitor	/	否
HY-134472	PI3Kδ-IN-8	Inhibitor	/	否
HY-159852	BBO-10203		/	否
HY-162878	CHF-6523	Inhibitor	/	否
HY-10116	PI-540	Inhibitor	/	否
HY-101776	Desmethyl-VS-5584	Inhibitor	/	否
HY-105666	TGX-155	Inhibitor	/	否
HY-106006	RV-1729	Inhibitor	/	否
HY-108958	(Rac)-AZD8186	Inhibitor	/	否
HY-108959	D-87503	Inhibitor	/	否
HY-111137	Puquitinib	Inhibitor	/	否
HY-111172	Inotilone	Inhibitor	/	否
HY-111209	Pichromene	Inhibitor	/	否
HY-112191	PI3K-IN-10	Inhibitor	/	否
HY-113817	SHIP1 activator 1		/	否
HY-114457	Phosphatidylinositol 4,5-bisphosphate		/	否
HY-114923	SU-11752	Inhibitor	/	否
HY-116431	I-BOP	Agonist	/	否
HY-116497	PH11	Inhibitor	/	否
HY-116604	RLX	Inhibitor	/	否
HY-118712	mTOR inhibitor WYE-23	Inhibitor	/	否
HY-120135	LTURM 36	Inhibitor	/	否
HY-121012	(rac)-AG-205		/	否
HY-121246S	Fluorofenidone-d3		/	否
HY-12279F	Umbralisib R-enantiomer	Inhibitor	99.52%	否
HY-123849	SN32976	Inhibitor	/	否
HY-123862	LAS195319	Inhibitor	/	否
HY-124647	PI3Kα-IN-1	Inhibitor	/	否
HY-124834	Nrf2 activator-10		/	否
HY-125376	PI3Kδ-IN-3	Inhibitor	/	否
HY-126083	17β-Hydroxywortmannin	Inhibitor	/	否
HY-128634	Anticancer agent 164		/	否
HY-131055	Mytoxin B		/	否
HY-131910A	(R)-IHMT-PI3Kδ-372	Inhibitor	99.75%	否
HY-132276	PtdIns-(3,4,5)-P3-biotin sodium		/	否
HY-132898	PI3K-IN-23	Activator	/	否
HY-135526	Demethoxyviridiol	Inhibitor	/	否
HY-136806	PI3K-IN-12	Inhibitor	/	否
HY-13685S1	Miltefosine-d4	Inhibitor	/	否
HY-139832	MCX 28	Inhibitor	/	否
HY-139880	PI3Kγ inhibitor 5	Inhibitor	/	否
HY-141476	PI3K/mTOR Inhibitor-3	Inhibitor	/	否
HY-14152	Prucalopride hydrochloride	Agonist	/	否
HY-141690A	PI3K-IN-19 hydrochloride	Inhibitor	/	否
HY-142676	PI3K-IN-26	Inhibitor	/	否
HY-142677	PI3K-IN-27		/	否
HY-143472	PI3Kδ-IN-11		/	否
HY-144059	AKT-IN-9	Inhibitor	/	否
HY-144060	AKT-IN-10	Inhibitor	/	否
HY-144254	PI3Kδ-IN-10		/	否
HY-144295	PI3Kα-IN-5	Inhibitor	/	否
HY-144450	PI3K-IN-29	Inhibitor	/	否
HY-144686	ATM Inhibitor-3	Inhibitor	/	否
HY-144687	ATM Inhibitor-4	Inhibitor	/	否
HY-144692	MEK/PI3K-IN-1	Inhibitor	/	否
HY-144693	MEK/PI3K-IN-2	Inhibitor	/	否
HY-145338	PI3Kβ-IN-1	Inhibitor	/	否
HY-145358	FAP-PI3KI1	Inhibitor	/	否
HY-145432	PI3K-IN-28	Inhibitor	/	否
HY-146016	PI3K/mTOR Inhibitor-5	Inhibitor	/	否
HY-146159	PI3K/HDAC-IN-2	Inhibitor	/	否
HY-146200	PI3K/mTOR Inhibitor-8	Inhibitor	/	否
HY-146260	NVP-CLR457	Inhibitor	/	否
HY-146504	Topoisomerase I/II inhibitor 3		/	否
HY-146743	Antitumor agent-53	Inducer	/	否
HY-146789	PI3Kδ/γ-IN-2	Inhibitor	/	否
HY-146835S	(Rac)-16:0PI(3,5)P2-d5 ammonium		/	否
HY-147285	PI3K/mTOR Inhibitor-9	Inhibitor	/	否
HY-147567	ATR-IN-15	Inhibitor	/	否
HY-147613	PI3K/mTOR Inhibitor-6	Inhibitor	/	否
HY-147614	PI3K/mTOR Inhibitor-7	Inhibitor	/	否
HY-147767	PI3Kα-IN-6		/	否
HY-147792	WNY1613	Inhibitor	/	否
HY-147898	PI3K-IN-33		/	否
HY-147899	PI3K-IN-34		/	否
HY-147900	PI3K-IN-35		/	否
HY-147911	COX-2/PI3K-IN-1	Inhibitor	/	否
HY-147912	COX-2/PI3K-IN-2	Inhibitor	/	否
HY-147913	PI3K/Akt/mTOR-IN-3		/	否
HY-147966	HDAC-IN-43	Inhibitor	/	否
HY-147983	PI3Kα-IN-8		/	否
HY-148317	PI3Kγ inhibitor 6	Inhibitor	/	否
HY-149000	PI3Kα-IN-7		/	否
HY-149092	Anticancer agent 109		/	否
HY-149205	CXJ-2	Inhibitor	/	否
HY-149235	PI3Kδ-IN-12	Inhibitor	/	否
HY-149427	PI3Kα-IN-12	Inhibitor	/	否
HY-149472	Anti-osteoporosis agent-4	Inhibitor	/	否
HY-149493	IHMT-PI3K-455	Inhibitor	/	否
HY-149521	PI3K-IN-47	Inhibitor	/	否
HY-149539	PLM-101	Inhibitor	/	否
HY-149556	MTX-241F	Inhibitor	/	否
HY-149634	PI3Kδ-IN-17	Inhibitor	/	否
HY-149669	PH14	Inhibitor	99.29%	否
HY-150034	PI3K-IN-38	Inhibitor	/	否
HY-150061	NVP-BBD130	Inhibitor	/	否
HY-150587	Anti-inflammatory agent 31	Inhibitor	/	否
HY-150638	PI3Kδ/γ-IN-3		/	否
HY-151635	PI3K/VEGFR2-IN-1		/	否
HY-151915	ATR-IN-20	Inhibitor	/	否
HY-152238	PI3K/mTOR Inhibitor-12	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-152774	Antitumor agent-86	Inhibitor	/	否
HY-153120	PI3K/mTOR Inhibitor-13	Inhibitor	/	否
HY-153306A	(S)-RLY-2608	Control	/	否
HY-153703	PI3Kγ inhibitor 7	Inhibitor	/	否
HY-153915	PI3Kα-IN-11	Inhibitor	95.35%	否
HY-155124	Antiproliferative agent-32	Inducer	/	否
HY-155180	FD2056	Inhibitor	/	否
HY-155520	Antileishmanial agent-19	Inhibitor	/	否
HY-155570	Anticancer agent 137		/	否
HY-155730	PI3K-IN-41	Inhibitor	/	否
HY-155833	PI3Kδ-IN-13	Inhibitor	/	否
HY-155890	Fimepinostat mesylate		/	否
HY-155975	PI3Kδ-IN-14	Inhibitor	/	否
HY-155996	FD2157		/	否
HY-156018	PI3Kα-IN-13	Inhibitor	/	否
HY-156080	PI3K-IN-48	Inhibitor	/	否
HY-156091	PI3Kα/HDAC6-IN-1	Inhibitor	/	否
HY-15643B	LY 303511 dihydrochloride		/	否
HY-156445	PI3K/mTOR Inhibitor-14	Inhibitor	/	否
HY-157125	PI3Kα-IN-14		/	否
HY-157128	PI3Kδ-IN-18	Inhibitor	/	否
HY-157287	(S)-Phe-A110/B319		/	否
HY-157295	PI3K/HDAC-IN-3	Inhibitor	/	否
HY-157319	PI3Kα-IN-15	Inhibitor	/	否
HY-157652	18:0-20:4 PI(3,4,5)P3		/	否
HY-157704	18:1 PI(3)P		/	否
HY-157707	18:1 PI(3,4,5)P3		/	否
HY-157714	08:0 PI(3,4)P2		/	否
HY-158017	WXM-1-170		/	否
HY-158029	PI3Kα-IN-21		/	否
HY-158050	PXB17	Inhibitor	/	否
HY-158147	PI3Kδ-IN-20	Inhibitor	/	否
HY-158156	NF-κB-IN-16		/	否
HY-158688	PI3Kδ-IN-21	Inhibitor	/	否
HY-159510	VEGFR-2-IN-51		/	否
HY-159517	PI3K/Akt/mTOR-IN-5		/	否
HY-159577	Nic-15	Modulator	/	否
HY-159892	PD-1/PD-L1-IN-54		/	否
HY-160282	PI3K-IN-49	Inhibitor	/	否
HY-160283	PI3K-IN-50	Inhibitor	/	否
HY-160418	PI3K-IN-51	Inhibitor	/	否
HY-160864	Torbafylline	Inhibitor	/	否
HY-161140	PI3Kα-IN-16	Inhibitor	/	否
HY-161144	AKT-IN-21		/	否
HY-161301	PI3K-IN-52	Inhibitor	/	否
HY-161362	SR-3-65		/	否
HY-161373	PI3Kα-IN-22	Inhibitor	/	否
HY-161816	PI3K/AKT-IN-3		/	否
HY-161852	PI3K-IN-55		/	否
HY-161858	EpskA21		/	否
HY-161874	RPS6-IN-1		/	否
HY-161968	EGFR/PI3Kα-IN-1	Inhibitor	/	否
HY-162268	MALT1-IN-13		/	否
HY-162292	Anticancer agent 190	Inhibitor	/	否
HY-162647	PI3Kδ-IN-22	Inhibitor	/	否
HY-162802	PI3K/AKT-IN-4		/	否
HY-162848	IHMT-PI3K-315	Inhibitor	/	否
HY-163151	JE-133	Inhibitor	/	否
HY-163360	PI3Kα-IN-19	Inhibitor	/	否
HY-163361	PI3Kα-IN-20	Inhibitor	/	否
HY-163501	PI3Kα-IN-23	Inhibitor	/	否
HY-163511	PI3K/Akt/mTOR-IN-4		/	否
HY-163533	CPD-002	Inhibitor	/	否
HY-163538	TYM-3-98		/	否
HY-163853	Antidiabetic agent 6	Activator	/	否
HY-165099	C-8 Ceramide-1-phosphate		/	否
HY-167843	Alborixin	Inhibitor	/	否
HY-168319	PI3Kγ ligand 1		/	否
HY-168608	TRPM7-IN-1		/	否
HY-168609	CRI9		/	否
HY-168718	FAK-IN-22		/	否
HY-168858	TRK-IN-30		/	否
HY-168893	K882		/	否
HY-169019	XJTU-L453		/	否
HY-169100	Antiproliferative agent-57	Inhibitor	/	否
HY-169121	DA-143	Inhibitor	/	否
HY-169212	I194496	Inhibitor	/	否
HY-169403	NW16		/	否
HY-169413	AKT-IN-25	Inhibitor	/	否
HY-169983	PI3Kδ-IN-23	Inhibitor	/	否
HY-170648	TS-IN-5		/	否
HY-170656	PI3K/mTOR Inhibitor-17	Inhibitor	/	否
HY-172130	PI3Kδ/BET-IN-1	Inhibitor	/	否
HY-172139	PI3Kα-IN-25	Inhibitor	/	否
HY-18085S	Quercetin-d5		/	否
HY-18085S2	Quercetin-13C3		/	否
HY-19535B	Nemiralisib succinate	Inhibitor	/	否
HY-48869	PI3K-IN-46		≥98.0%	否
HY-B0093AS	Benazepril-d5 hydrochloride	Inhibitor	/	否
HY-N0361S	Dihydrocapsaicin-d3		/	否
HY-N0451R	Acacetin (Standard)	Inducer	/	否
HY-N0728A	α-Linolenic acid sodium	Inhibitor	/	否
HY-N0728R	α-Linolenic acid (Standard)	Inhibitor	/	否
HY-N0728S2	α-Linolenic acid-d14	Inhibitor	/	否
HY-N0776R	Isorhamnetin (Standard)	Inhibitor	/	否
HY-N10106	Dihydromyristicin	Inhibitor	99.85%	否
HY-N10802	6-O-Isobutyrylbritannilactone	Inhibitor	/	否
HY-N12044	Asparanin A	Inducer	/	否
HY-N12959	5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone	Inhibitor	/	否
HY-N13063	Anticancer agent 235		/	否
HY-N1338	Royleanone	Inhibitor	/	否
HY-N1904	4′-Hydroxywogonin		/	否
HY-N3542	Carpachromene	Inhibitor	/	否
HY-N3720	Demethoxycapillarisin	Inhibitor	/	否
HY-N8884	Coelonin	Inhibitor	/	否
HY-N8931	Monomethyl lithospermate	Activator	/	否
HY-N9602	6,7,4'-Trihydroxyflavanone		/	否
HY-P0175A	740 Y-P TFA		/	否
HY-P10090	Apoptin-derived peptide		/	否
HY-P10093	Penetratin-PI3Kγ(126-150)	Inhibitor	/	否
HY-P10320	T3 Peptide	Activator	/	否
HY-P10323	T7 Peptide		/	否
HY-P4790	Acetyl-Exenatide	Inhibitor	/	否
HY-RS10463	PI3 Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W010201R	Citronellol (Standard)		/	否
HY-W040417	Boc-L-cyclobutylglycine		98.91%	否
HY-100603A	(S)-GSK-F1	Inhibitor	/	否
HY-10202B	Tandutinib sulfate		/	否
HY-10549	PI3Kγ inhibitor 1	Inhibitor	/	否
HY-111058	D-106669	Inhibitor	/	否
HY-113572	PX-866-17OH	Inhibitor	/	否
HY-116191	WJD008	Inhibitor	/	否
HY-116563	PI3Kα-IN-24	Inhibitor	/	否
HY-117885	PF-5177624	Inhibitor	/	否
HY-117923	PF-06465603	Inhibitor	/	否
HY-118374	AM-9635	Inhibitor	/	否
HY-120265	MIPS-9922	Inhibitor	/	否
HY-120471	AM-0687	Inhibitor	/	否
HY-121672	PI3K-IN-7		/	否
HY-121684	Ramentaceone		/	否
HY-123790	AS2541019	Inhibitor	/	否
HY-124535	TGX-115	Inhibitor	/	否
HY-12491	PIK-C98		/	否
HY-12517	GNE-293	Inhibitor	/	否
HY-14153S	Tegaserod-d11		/	否
HY-143276	(S,S,R)-AHPC-C6-NH2		/	否
HY-143277	HL-2		/	否
HY-150309	PI3K-IN-54	Inhibitor	/	否
HY-15288	PI3kδ inhibitor 1	Inhibitor	/	否
HY-155211	mTOR inhibitor-13	Inhibitor	/	否
HY-15643	LY 303511		/	否
HY-157288	(R)-Phe-A110/B319		/	否
HY-157706	PI(3,4)P2 (18:1) (ammonium salt)	Activator	/	否
HY-160458	PI3Kα-IN-17	Inhibitor	/	否
HY-16122	CAL-130 Racemate	Inhibitor	/	否
HY-16122A	CAL-130	Inhibitor	/	否
HY-162023	mTOR inhibitor-10	Inhibitor	/	否
HY-162024	mTOR inhibitor-16	Inhibitor	/	否
HY-162025	mTOR inhibitor-17	Inhibitor	/	否
HY-164384	DFX117		/	否
HY-164662	mTOR inhibitor-24	Inhibitor	/	否
HY-167876	PQR514		/	否
HY-167952	mTOR inhibitor-25		/	否
HY-50673A	Dactolisib hydrochloride		/	否
HY-B1234S	Octinoxate-13C,d3		/	否
HY-N13164	Polygalacin D3		/	否
HY-N13176	Stellettin B		/	否
HY-N2037AS1	Higenamine-d4-1 hydrochloride		/	否
HY-N8380	(-)-Latifolin		/	否
HY-P10393	ERα17p	Inducer	/	否
HY-W636234	GSK2636771 methyl	Inhibitor	/	否
HY-122593	PI3Kδ-IN-5	Inhibitor	99.62%	否
HY-18310	NIBR-17	Inhibitor	/	否
HY-112602	PI3K/mTOR Inhibitor-1	Inhibitor	/	否
HY-112286	PI3Kγ inhibitor 2	Inhibitor	/	否
HY-112439	PI3Kdelta inhibitor 1	Inhibitor	/	否
HY-112614	ATM Inhibitor-1	Inhibitor	/	否
HY-118236	(S)-AZD 6482		/	否

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.